Floatz logo

Lurasidone

Chronic Schizophrenia

Sumitomo Pharma America, Inc.Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

145 Active assets in the Chronic Schizophrenia cohort.

View all 50

Same molecule, other indications

Lurasidone is also rated in:

bipolar depressionDormant
A
Indicative ·
82 / 100
View asset →
bipolar I disorderDormant
BBB
Indicative ·
79 / 100
View asset →
schizoaffective disorderDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →